✦ LIBER ✦

Immunotherapy of cancer with a pressurized, surface reduced tumor-cell vaccine

✍ Scribed by Yechiel Goldman; Meir Shinitzky

Publisher: John Wiley and Sons
Year: 2000
Tongue: English
Weight: 359 KB
Volume: 50
Category: Article
ISSN: 0272-4391
DOI: 10.1002/1098-2299(200007/08)50:3/4<272::aid-ddr10>3.0.co;2-h

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Antigen-specific cancer immunotherapy us

Antigen-specific cancer immunotherapy using a GM-CSF secreting allogeneic tumor cell-based vaccine

✍ Edwin Y. Chang; Chien-Hung Chen; Hongxiu Ji; Tian-Li Wang; Kenneth Hung; Bruce P 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 French ⚖ 147 KB

Granulocyte-macrophage colony-stimulating factor (GM-CSF)-transduced autologous tumor cell-based vaccines are currently one of the major forms of cancer vaccines. However, the preparation of GM-CSF-transduced autologous tumor vaccines is time-consuming and technically challenging. In addition, the h

Vaccination with recoverin, a cancer-ass

Vaccination with recoverin, a cancer-associated retinopathy antigen, induces autoimmune retinal dysfunction and tumor cell regression in mice

✍ Akiko Maeda; Tadao Maeda; Hiroshi Ohguro; Krzysztof Palczewski; Noriyuki Sato 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 228 KB 👁 2 views

A phase-I clinical study of autologous t

A phase-I clinical study of autologous tumor cells plus interleukin-2-gene-transfected allogeneic fibroblasts as a vaccine in patients with cancer

✍ Hendrik Veelken; Andreas Mackensen; Michael Lahn; Gabriele Köhler; Daniel Becker 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 French ⚖ 257 KB 👁 2 views

Tumor cells transfected to express immunostimulatory cytokines, or admixed with similarly modified bystander cells, are able to induce immune responses against unmodified tumor cells in animal models. For treatment of human patients, a vaccine composed of autologous tumor cells and IL-2-secreting al

Characterization of paired tumor and non

Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer

✍ Adi F. Gazdar; Venkatesh Kurvari; Arvind Virmani; Lauren Gollahon; Masahiro Saka 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 French ⚖ 161 KB 👁 2 views

The goal of our study was to develop a panel of tumor cell lines along with paired non-malignant cell lines or strains collected from breast cancers, predominantly primary tumors. From a total of 189 breast tumor samples consisting of 177 primary tumors and 12 metastatic tissues, we established 21 h

Ratio of IgG: IgM antibodies to sialyl L

Ratio of IgG: IgM antibodies to sialyl LewisX and GM3 correlates with tumor growth after immunization with melanoma-cell vaccine with different adjuvants in mice

✍ Mepur H. Ravindranath; Mark C. Kelley; Ralph C. Jones; Amir A. Amiri; Philip M. 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 French ⚖ 190 KB 👁 2 views

Human melanoma cells (from biopsies and culture) express sialyl-Lewis x and sialyl Lewis a , the ligands for ECAM. These ligands may facilitate tumor progression and metastasis in human cancers. To test whether the antibodies to these ligands inhibit tumor progression, IgG and IgM responses to sLe x

CD80 expression in an HLA-A2-positive hu

CD80 expression in an HLA-A2-positive human non-small cell lung cancer cell line enhances tumor-specific cytotoxicity of HLA-A2-positive T cells derived from a normal donor and a patient with non-small cell lung cancer

✍ Dale L. Bixby; John R. Yannelli 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 French ⚖ 185 KB 👁 2 views

To generate non-small cell lung cancer (NSCLC)-reactive lymphocytes, we transfected an HLA-A2-expressing human NSCLC line (1355) with the cDNA encoding the lymphocyte co-stimulatory molecule CD80. Following selection in G418, 1355.7 demonstrated stable cell-surface expression of CD80. Allogeneic mix